IO Biotech develops new cancer treatments, that have proven to give outstanding responses in combination with current standard of care in melanoma (skin cancer) and Non-small cell lung cancer.
Eir Ventures is delighted to announce our participation in the over subscribed € 127M series B round in IO Biotech. IO Biotech develops new cancer treatments, that have proven to give outstanding responses in combination with current standard of care in melanoma (skin cancer) and Non-small cell lung cancer. With the funding from this financing, the company can take it’s lead product through late stage clinical development to registration. It is one of the largest private rounds for any Scandinavian biotech company.